Sugammadex (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Sugammadex" in English language version.

refsWebsite

Global rank English rank

11web.archive.org

1^st place

11nih.gov

4^th place

8doi.org

2^nd place

3europa.eu

68^th place

117^th place

2tga.gov.au

3,984^th place

2,622^nd place

2semanticscholar.org

11^th place

8^th place

2schering-plough.com

low place

2fda.gov

447^th place

338^th place

1canada.ca

1,712^th place

1,063^rd place

1medicines.org.uk

3,823^rd place

2,387^th place

1merckconnect.com

low place

1adisonline.com

low place

adisonline.com

Yang LP, Keam SJ (2009). "Sugammadex: a review of its use in anaesthetic practice". Drugs. 69 (7): 919–942. doi:10.2165/00003495-200969070-00008. PMID 19441874. S2CID 195685307. Archived from the original on 2011-10-08. Retrieved 2010-03-29.

canada.ca

"Health Canada New Drug Authorizations: 2016 Highlights". Health Canada. 14 March 2017. Retrieved 7 April 2024.

doi.org

Miller RD (March 2007). "Sugammadex: an opportunity to change the practice of anesthesiology?". Anesthesia and Analgesia. 104 (3): 477–478. doi:10.1213/01.ane.0000255645.64583.e8. PMID 17312188.
Eleveld DJ, Kuizenga K, Proost JH, Wierda JM (March 2007). "A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex". Anesthesia and Analgesia. 104 (3): 582–584. doi:10.1213/01.ane.0000250617.79166.7f. PMID 17312212. S2CID 34811540.
Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, et al. (August 2008). "Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial". Anesthesiology. 109 (2): 188–197. doi:10.1097/ALN.0b013e31817f5bc7. PMID 18648227.
Abrishami A, Ho J, Wong J, Yin L, Chung F (October 2009). Abrishami A (ed.). "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". The Cochrane Database of Systematic Reviews (4): CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409.
Hristovska AM, Duch P, Allingstrup M, Afshari A (August 2017). "Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults". The Cochrane Database of Systematic Reviews. 8 (8): CD012763. doi:10.1002/14651858.cd012763. PMC 6483345. PMID 28806470.
Brueckmann B, Sasaki N, Grobara P, Li MK, Woo T, de Bie J, et al. (November 2015). "Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study". British Journal of Anaesthesia. 115 (5): 743–751. doi:10.1093/bja/aev104. PMID 25935840.
Yang LP, Keam SJ (2009). "Sugammadex: a review of its use in anaesthetic practice". Drugs. 69 (7): 919–942. doi:10.2165/00003495-200969070-00008. PMID 19441874. S2CID 195685307. Archived from the original on 2011-10-08. Retrieved 2010-03-29.
Naguib M (March 2007). "Sugammadex: another milestone in clinical neuromuscular pharmacology". Anesthesia and Analgesia. 104 (3): 575–581. doi:10.1213/01.ane.0000244594.63318.fc. PMID 17312211.

europa.eu

ema.europa.eu

"Bridion EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 10 June 2020. Retrieved 10 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Sugammadex Adroiq". European Medicines Agency. 16 June 2023. Retrieved 19 June 2023.

ec.europa.eu

"Sugammadex Adroiq". Union Register of medicinal products. 30 May 2023. Retrieved 6 June 2023.

fda.gov

accessdata.fda.gov

"Bridion (sugammadex) Injection". U.S. Food and Drug Administration (FDA). 4 February 2016. Archived from the original on 10 June 2020. Retrieved 10 June 2020.

fda.gov

"FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery" (Press release). Food and Drug Administration. 2015-12-15. Archived from the original on 2015-12-15. Retrieved 2015-12-15.

medicines.org.uk

"Bridion 100 mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 18 March 2021. Archived from the original on 27 June 2021. Retrieved 27 June 2021.

merckconnect.com

"Dosing for Bridion (sugammadex)". www.merckconnect.com. Archived from the original on 2019-01-12. Retrieved 2019-01-11.

nih.gov

pubmed.ncbi.nlm.nih.gov

Miller RD (March 2007). "Sugammadex: an opportunity to change the practice of anesthesiology?". Anesthesia and Analgesia. 104 (3): 477–478. doi:10.1213/01.ane.0000255645.64583.e8. PMID 17312188.
Eleveld DJ, Kuizenga K, Proost JH, Wierda JM (March 2007). "A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex". Anesthesia and Analgesia. 104 (3): 582–584. doi:10.1213/01.ane.0000250617.79166.7f. PMID 17312212. S2CID 34811540.
Welliver M (October 2006). "New drug sugammadex: a selective relaxant binding agent". AANA Journal. 74 (5): 357–363. PMID 17048555.
Pühringer FK, Rex C, Sielenkämper AW, Claudius C, Larsen PB, Prins ME, et al. (August 2008). "Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial". Anesthesiology. 109 (2): 188–197. doi:10.1097/ALN.0b013e31817f5bc7. PMID 18648227.
Abrishami A, Ho J, Wong J, Yin L, Chung F (October 2009). Abrishami A (ed.). "Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade". The Cochrane Database of Systematic Reviews (4): CD007362. doi:10.1002/14651858.CD007362.pub2. PMID 19821409.
Hristovska AM, Duch P, Allingstrup M, Afshari A (August 2017). "Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults". The Cochrane Database of Systematic Reviews. 8 (8): CD012763. doi:10.1002/14651858.cd012763. PMC 6483345. PMID 28806470.
Brueckmann B, Sasaki N, Grobara P, Li MK, Woo T, de Bie J, et al. (November 2015). "Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study". British Journal of Anaesthesia. 115 (5): 743–751. doi:10.1093/bja/aev104. PMID 25935840.
Yang LP, Keam SJ (2009). "Sugammadex: a review of its use in anaesthetic practice". Drugs. 69 (7): 919–942. doi:10.2165/00003495-200969070-00008. PMID 19441874. S2CID 195685307. Archived from the original on 2011-10-08. Retrieved 2010-03-29.
Naguib M (March 2007). "Sugammadex: another milestone in clinical neuromuscular pharmacology". Anesthesia and Analgesia. 104 (3): 575–581. doi:10.1213/01.ane.0000244594.63318.fc. PMID 17312211.

dailymed.nlm.nih.gov

"Bridion- sugammadex injection, solution". DailyMed. 14 December 2018. Archived from the original on 10 June 2020. Retrieved 10 June 2020.

ncbi.nlm.nih.gov

Hristovska AM, Duch P, Allingstrup M, Afshari A (August 2017). "Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults". The Cochrane Database of Systematic Reviews. 8 (8): CD012763. doi:10.1002/14651858.cd012763. PMC 6483345. PMID 28806470.

schering-plough.com

"U.S. FDA Issues Action Letter for Sugammadex" (Press release). Schering-Plough. 2008-08-01. Archived from the original on 2008-08-10. Retrieved 2008-08-02.
"Bridion (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union" (Press release). Schering-Plough. 2008-07-29. Archived from the original on 2008-09-24. Retrieved 2008-08-02.

semanticscholar.org

api.semanticscholar.org

Eleveld DJ, Kuizenga K, Proost JH, Wierda JM (March 2007). "A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex". Anesthesia and Analgesia. 104 (3): 582–584. doi:10.1213/01.ane.0000250617.79166.7f. PMID 17312212. S2CID 34811540.
Yang LP, Keam SJ (2009). "Sugammadex: a review of its use in anaesthetic practice". Drugs. 69 (7): 919–942. doi:10.2165/00003495-200969070-00008. PMID 19441874. S2CID 195685307. Archived from the original on 2011-10-08. Retrieved 2010-03-29.

tga.gov.au

SUGAMMADEX ACCORD (Accord Healthcare Pty Ltd) Archived 2022-10-12 at the Wayback Machine Department of Health and Aged Care. Retrieved 30 March 2023
SUGAMMADEX SANDOZ (Sandoz Pty Ltd) Archived 2022-10-12 at the Wayback Machine Department of Health and Aged Care. Retrieved 30 March 2023

web.archive.org

SUGAMMADEX ACCORD (Accord Healthcare Pty Ltd) Archived 2022-10-12 at the Wayback Machine Department of Health and Aged Care. Retrieved 30 March 2023
SUGAMMADEX SANDOZ (Sandoz Pty Ltd) Archived 2022-10-12 at the Wayback Machine Department of Health and Aged Care. Retrieved 30 March 2023
"Bridion 100 mg/ml solution for injection - Summary of Product Characteristics (SmPC)". (emc). 18 March 2021. Archived from the original on 27 June 2021. Retrieved 27 June 2021.
"Bridion- sugammadex injection, solution". DailyMed. 14 December 2018. Archived from the original on 10 June 2020. Retrieved 10 June 2020.
"Bridion EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 10 June 2020. Retrieved 10 June 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
"Dosing for Bridion (sugammadex)". www.merckconnect.com. Archived from the original on 2019-01-12. Retrieved 2019-01-11.
Yang LP, Keam SJ (2009). "Sugammadex: a review of its use in anaesthetic practice". Drugs. 69 (7): 919–942. doi:10.2165/00003495-200969070-00008. PMID 19441874. S2CID 195685307. Archived from the original on 2011-10-08. Retrieved 2010-03-29.
"U.S. FDA Issues Action Letter for Sugammadex" (Press release). Schering-Plough. 2008-08-01. Archived from the original on 2008-08-10. Retrieved 2008-08-02.
"Bridion (sugammadex) Injection". U.S. Food and Drug Administration (FDA). 4 February 2016. Archived from the original on 10 June 2020. Retrieved 10 June 2020.
"FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery" (Press release). Food and Drug Administration. 2015-12-15. Archived from the original on 2015-12-15. Retrieved 2015-12-15.
"Bridion (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union" (Press release). Schering-Plough. 2008-07-29. Archived from the original on 2008-09-24. Retrieved 2008-08-02.